As weight loss lead­ers boom, one biotech con­tender aban­dons its quest with Chap­ter 7 liq­ui­da­tion

Weight loss drugs were her­ald­ed as one of the biggest in­no­va­tions in bio­phar­ma in 2023, as the GLP-1 con­tenders swelled in­to megablock­busters. But for one small biotech look­ing to make it big in the busi­ness of shed­ding pounds, this year marks the end of the line on a long and wind­ing trail that led to biotech Boot Hill.

Gele­sis, which was backed by PureTech, qui­et­ly filed for Chap­ter 7 bank­rupt­cy liq­ui­da­tion mid-week, weeks af­ter PureTech gave up on a plan to bring the strug­gling out­fit back in­to the fold. PureTech is led by Daphne Zo­har, who is mar­ried to Gele­sis founder and CEO Yishai Zo­har, though a spokesper­son tells End­points News that she re­cused her­self from any of the de­ci­sion-mak­ing re­gard­ing Gele­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER